Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Would Market Qnexa With Pregnancy Category X Designation If Approved

This article was originally published in The Pink Sheet Daily

Executive Summary

With a strict REMS its only possible future, the weight-loss drug is unaffected by FDA decision to reclassify the topiramate portion of the combination drug as Pregnancy Category D.

You may also be interested in...



Vivus Will Cut Population In Qnexa Resubmission

The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.

Vivus Will Cut Population In Qnexa Resubmission

The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.

Obesity Drug Developers Aim To Navigate Regulatory Backroads

The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel